Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation

[1]  J. Debus,et al.  Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. , 2010, International journal of radiation oncology, biology, physics.

[2]  S. Leenstra,et al.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide , 2010, British Journal of Cancer.

[3]  Zhongwu Chen,et al.  Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. , 2010, Neuro-oncology.

[4]  W. Woodward,et al.  Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. , 2010, International journal of radiation oncology, biology, physics.

[5]  J. Wong,et al.  HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. , 2009, Cancer biotherapy & radiopharmaceuticals.

[6]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[7]  R. Stupp,et al.  Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. , 2008, Acta neurologica Belgica.

[8]  K. Camphausen,et al.  Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid , 2008, Clinical Cancer Research.

[9]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide , 2008, Clinical Cancer Research.

[10]  S. Leenstra,et al.  Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. , 2007, International journal of radiation oncology, biology, physics.

[11]  T. Akagi,et al.  O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies , 2007, Molecular Cancer.

[12]  J. Wolff,et al.  Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines , 2007, Journal of Neuro-Oncology.

[13]  W. Yung,et al.  Fatal reactivation of hepatitis B with temozolomide. , 2007, The New England journal of medicine.

[14]  Abraham Nudelman,et al.  In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. , 2007, Neuro-oncology.

[15]  K. Aldape,et al.  Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.

[16]  A. El-Osta,et al.  The Epigenetic Modifier, Valproic Acid, Enhances Radiation Sensitivity , 2006, Epigenetics.

[17]  Jin Ho Kim,et al.  Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 , 2006, Clinical Cancer Research.

[18]  S. Vandenberg,et al.  Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.

[19]  A. El-Osta,et al.  The histone deacetylase inhibitor, trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X , 2005, Cancer biology & therapy.

[20]  P. Harari,et al.  Modulation of radiation response by histone deacetylase inhibition. , 2005, International journal of radiation oncology, biology, physics.

[21]  C. Marosi,et al.  P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy , 2005, Journal of Neuro-Oncology.

[22]  K. Camphausen,et al.  Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid , 2005, International journal of cancer.

[23]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[24]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[25]  K. Camphausen,et al.  Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation , 2004, Clinical Cancer Research.

[26]  Jin Ho Kim,et al.  Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. , 2004, International journal of radiation oncology, biology, physics.

[27]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[28]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[29]  M. Berger,et al.  The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents , 2003, Molecular and Cellular Biology.

[30]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[31]  M. Szyf,et al.  Valproate Induces Replication-independent Active DNA Demethylation* , 2003, Journal of Biological Chemistry.

[32]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[33]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[34]  J. Heimans,et al.  Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.

[35]  J. Jiricny,et al.  Involvement of the mismatch repair system in temozolomide-induced apoptosis. , 1998, Molecular pharmacology.

[36]  J. Dichgans,et al.  Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells , 1998, Journal of Neuro-Oncology.

[37]  B. Kaina,et al.  Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. , 1997, Mutation research.

[38]  D. Graham,et al.  D‐1 Dopaminergic and β‐Adrenergic Stimulation of Adenylate Cyclase in a Clone Derived from the Human Astrocytoma Cell Line G‐CCM , 1986, Journal of neurochemistry.

[39]  G. Margison,et al.  Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Calatozzolo,et al.  Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. , 2007, Oncology research.

[41]  Z. Kostrouch,et al.  Valproic acid, a molecular lead to multiple regulatory pathways. , 2007, Folia biologica.

[42]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.